PNPLA3 targeting small interfering RNA - Argo Biopharma
Latest Information Update: 05 Mar 2024
At a glance
- Originator Argo Biopharma
- Class Hepatoprotectants; Small interfering RNA
- Mechanism of Action Adiponutrin expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Non-alcoholic fatty liver disease
Most Recent Events
- 20 Feb 2024 PNPLA3 targeting small interfering RNA is available for licensing as of 20 Feb 2024. https://www.argobiopharma.com/partnering/index.html prior to February 2024 (Argo Biopharma pipeline, February 2024)
- 20 Feb 2024 Preclinical trials in Non-alcoholic fatty liver disease in China (Parenteral), prior to February 2024 (Argo Biopharma pipeline, February 2024)